top of page

BIOS Clinical Research

BIOS specializes in infectious disease research, with a focus on HIV and PrEP. Our team of advisors and clinical research team have over 30 years of experience in infectious disease and LGBTQ+ care. We are affirming, inclusive,
and have trans staff.
 

Phone: 760.417.8089

info@biosclinicalresearch.com

Current Clinical Trials

 

A study to evaluate the long-term efficacy, safety, and durability of ibalizumab in combination with other ARVs by comparing the virologic, immunologic and clinical outcomes of patients receiving ibalizumab treatment versus patients not receiving ibalizumab. (Promise-US)

A study to evaluate the long-term efficacy, safety, and durability of ibalizumab in combination with other ARVs 

 

The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogeneous real-world patient population. Additional data on the efficacy and safety of ibalizumab and its impact on patient reported outcomes will be captured until study end.

 

Primary Objective:

 

To evaluate the long-term efficacy, safety, and durability of ibalizumab in combination with other ARVs by comparing the virologic, immunologic and clinical outcomes of patients receiving ibalizumab treatment versus patients not receiving ibalizumab.

Website: https://www.clinicaltrials.gov/ct2/show/NCT05388474

Sponsor: Theratechnologies Study ID: TH-IBA-CTR-1003

Study to Assess the Effectiveness and Safety of Lenacapavir for Human Immunodeficiency Virus (HIV)
Pre-Exposure Prophylaxis (PURPOSE 2)

Study to Assess the Effectiveness and Safety of Lenacapavir for Human Immunodeficiency Virus (HIV) Pre-Exposure Prophylaxis

 

A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People ≥ 16 Years of Age Who Have Sex With Male Partners and Are at Risk for HIV Infection

Website: https://www.gileadclinicaltrials.com/study/?id=GS-US-528-9023

Sponsor: Gilead Study ID: GS-US-528-9023

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV 

 

A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

Website: https://www.gileadclinicaltrials.com/study/?id=GS-US-563-6041

Sponsor: Gilead Study ID: GS-US-563-6041

info@biosclinicalresearch.com

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (Artistry 1)

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy

 

An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens

Website: https://www.gileadclinicaltrials.com/study/?id=GS-US-621-6289

Sponsor: Gilead Study ID: GS-US-6289

info@biosclinicalresearch.com

bottom of page